Immunic Inc
IMUX0.573USD
+0.006+1.13%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
56.53MMarket Cap
LossP/E TTM
More Details of Immunic Inc Company
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Immunic Inc Info
Ticker SymbolIMUX
Company nameImmunic Inc
IPO dateApr 17, 2014
CEOVitt (Daniel)
Number of employees91
Security typeOrdinary Share
Fiscal year-endApr 17
Address1200 Avenue Of The Americas
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone13322559818
Websitehttps://imux.com/
Ticker SymbolIMUX
IPO dateApr 17, 2014
CEOVitt (Daniel)
Company Executives of Immunic Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Dr. Andreas Muehler, M.D.
Dr. Andreas Muehler, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Inderpal Singh
Mr. Inderpal Singh
General Counsel
General Counsel
--
--
Ms. Maria Toernsen
Ms. Maria Toernsen
Independent Director
Independent Director
--
--
Dr. Hella Kohlhof, Ph.D.
Dr. Hella Kohlhof, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
abrdn Inc.
6.85%
BVF Partners L.P.
6.36%
Avidity Partners Management LP
3.91%
The Vanguard Group, Inc.
3.61%
Morgan Stanley & Co. LLC
2.56%
Other
76.71%
Shareholders
Shareholders
Proportion
abrdn Inc.
6.85%
BVF Partners L.P.
6.36%
Avidity Partners Management LP
3.91%
The Vanguard Group, Inc.
3.61%
Morgan Stanley & Co. LLC
2.56%
Other
76.71%
Shareholder Types
Shareholders
Proportion
Hedge Fund
17.07%
Investment Advisor/Hedge Fund
9.19%
Investment Advisor
8.66%
Research Firm
2.84%
Individual Investor
1.08%
Bank and Trust
0.01%
Other
61.14%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
128
47.68M
48.33%
-7.09M
2025Q2
135
50.98M
53.18%
-8.45M
2025Q1
143
43.91M
45.87%
-16.90M
2024Q4
141
54.47M
60.46%
-15.06M
2024Q3
152
61.42M
68.19%
-8.79M
2024Q2
169
63.34M
74.84%
-9.30M
2024Q1
202
64.86M
76.52%
-3.93M
2023Q4
199
22.30M
46.89%
-13.27M
2023Q3
205
25.26M
53.96%
-11.93M
2023Q2
209
27.09M
58.47%
-12.08M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
abrdn Inc.
8.24M
8.36%
+7.18M
+678.11%
Jun 30, 2025
BVF Partners L.P.
7.65M
7.76%
-1.25M
-14.04%
Jun 30, 2025
Avidity Partners Management LP
5.62M
5.69%
+1.16M
+26.07%
Jun 30, 2025
The Vanguard Group, Inc.
4.13M
4.18%
+193.60K
+4.92%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.60M
3.65%
+3.07M
+576.90%
Jun 30, 2025
Focus Partners Wealth, LLC
2.54M
2.58%
-40.93K
-1.58%
Jun 30, 2025
Gratus Capital LLC
2.11M
2.14%
+56.86K
+2.77%
Jun 30, 2024
Laurion Capital Management LP
1.91M
1.93%
+1.68M
+733.98%
Jun 30, 2025
Soleus Capital Management, L.P.
7.29M
7.39%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
1.40M
1.42%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immunic Inc?
The top five shareholders of Immunic Inc are:
abrdn Inc. holds 8.24M shares, accounting for 8.36% of the total shares.
BVF Partners L.P. holds 7.65M shares, accounting for 7.76% of the total shares.
Avidity Partners Management LP holds 5.62M shares, accounting for 5.69% of the total shares.
The Vanguard Group, Inc. holds 4.13M shares, accounting for 4.18% of the total shares.
Morgan Stanley & Co. LLC holds 3.60M shares, accounting for 3.65% of the total shares.
abrdn Inc. holds 8.24M shares, accounting for 8.36% of the total shares.
BVF Partners L.P. holds 7.65M shares, accounting for 7.76% of the total shares.
Avidity Partners Management LP holds 5.62M shares, accounting for 5.69% of the total shares.
The Vanguard Group, Inc. holds 4.13M shares, accounting for 4.18% of the total shares.
Morgan Stanley & Co. LLC holds 3.60M shares, accounting for 3.65% of the total shares.
What are the top three shareholder types of Immunic Inc?
The top three shareholder types of Immunic Inc are:
abrdn Inc.
BVF Partners L.P.
Avidity Partners Management LP
abrdn Inc.
BVF Partners L.P.
Avidity Partners Management LP
How many institutions hold shares of Immunic Inc (IMUX)?
As of 2025Q3, 128 institutions hold shares of Immunic Inc, with a combined market value of approximately 47.68M, accounting for 48.33% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.85%.
What is the biggest source of revenue for Immunic Inc?
In --, the -- business generated the highest revenue for Immunic Inc, amounting to -- and accounting for --% of total revenue.
